Table 2.

Response to HCV therapy

Response to HCV therapy	Group A: HCV/HIV co-infected patients	Group B: HCV mono-infected patients	p-values
SVR all, n (%)	18/36 (50)	27/52 (52)	0.860
RVR, n (%)	9/36 (25)	17/52 (32)	0.440
EVR, n (%)	6/36 (17)	7/52 (13)	0.677
SVR GT 1, n (%)	5/15 (33)	11/27 (40)	0.626
SVR GT 2, n (%)	1/2 (50)	7/8 (87)	0.356
SVR GT 3, n (%)	9/14 (64)	7/12 (58)	0.756
SVR GT 4, n (%)	1/1 (100)	2/4 (50)	0.600
GT unknown, n (%)	2/36 (5)	0/52 (0)	0.809
SVR GT 1 + 4, n (%)	6/16 (37)	13/31 (41)	0.770
SVR GT 2 + 3, n (%)	10/16 (62)	14/20 (70)	0.636
Discontinuation of therapy, n (%)	3/36 (12)	4/52 (7)	0.305
Breakthrough infection, n (%)	1/36 (2)	0/52	0.410
Non-response, n (%)	5/36 (13)	3/52 (5)	0.130
Relapse, n (%)	7/36 (19)	9/52 (17)	0.482
Unknown, n (%)	2/36 (5)	9/52 (17)	0.105
SVR HAART treated patients, n (%)	14/29 (48)	n.a.	n.a.
SVR non-HAART treated patients, n (%)	4/7 (57)	n.a.	n.a.
SVR CD4 Nadir > 200/μl, n (%)	9/18 (50)	n.a.	n.a.
SVR CD4 Nadir < 200/μl, n (%)	9/18 (50)	n.a.	n.a.